Last updated: July 5, 2024
Sponsor: Vejle Hospital
Overall Status: Completed
Phase
N/A
Condition
Angina
Chest Pain
Myocardial Ischemia
Treatment
Cardiologic assessment
Clinical Study ID
NCT03486340
CATCH2018
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Histologically verified cancer
First-time treatment with 5-FU/Capecitabine
Expected remaining lifetime > 6 months
Informed consent
Exclusion
Exclusion Criteria:
Known ischemic heart disease
Ischemia-suspicious symptoms prior to 5-FU treatment
Ischemia-suspicious ECG-changes prior to 5-FU treatment
Study Design
Total Participants: 218
Treatment Group(s): 1
Primary Treatment: Cardiologic assessment
Phase:
Study Start date:
April 11, 2018
Estimated Completion Date:
June 07, 2024
Connect with a study center
Departments of Oncology and Medicine, Vejle Hospital
Vejle,
DenmarkSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.